{"id":985,"date":"2023-02-14T14:03:22","date_gmt":"2023-02-14T14:03:22","guid":{"rendered":"http:\/\/example.com\/?p=977"},"modified":"2023-02-14T14:03:22","modified_gmt":"2023-02-14T14:03:22","slug":"977-oncotype-map-testing","status":"publish","type":"post","link":"https:\/\/w2.geleleger.nl\/dckjms-977-oncotype-map-testing-wabjf\/","title":{"rendered":"Oncotype Map Testing"},"content":{"rendered":"<div class=\"387480d42754320bb6f0e83bf7886d44\" data-index=\"1\" style=\"float: none; margin:10px 0 10px 0; text-align:center;\">\n<script type=\"text\/javascript\">\r\n\tatOptions = {\r\n\t\t'key' : '4a1f1119f949a4af74d56b8a3af8b867',\r\n\t\t'format' : 'iframe',\r\n\t\t'height' : 250,\r\n\t\t'width' : 300,\r\n\t\t'params' : {}\r\n\t};\r\n\tdocument.write('<scr' + 'ipt type=\"text\/javascript\" src=\"http' + (location.protocol === 'https:' ? 's' : '') + ':\/\/bleedingofficecontagion.com\/4a1f1119f949a4af74d56b8a3af8b867\/invoke.js\"><\/scr' + 'ipt>');\r\n<\/script>\n<\/div>\n\n<p><strong>Oncotype Map Testing<\/strong>. <strong>These tests can help medical professionals. The Oncotype MAP test, previously known as PCDx, provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, allowing physicians to understand a. The Oncotype MAP test, previously known as PCDx, is a rapid, comprehensive tumor profiling panel that aids therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer. The Oncotype Map test report is easy to interpret with NCCN Compendium-based recommendations, along with potential evidence-based therapies and clinical trials. About the Oncotype DX \u00ae and Oncotype MAP\u2122 Portfolio of Tests. In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been What is Oncotype DX testing? Oncotype DX tests are genomic tests produced by Genomic Health, Inc., which is now part of the company Exact Sciences. Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences discusses the Oncotype MAP\u2122 Pan-Cancer Tissue test for patients with adva.<\/strong><\/p>\n<p><figure> \t\t<img decoding=\"async\" src=\"https:\/\/www.researchgate.net\/profile\/Sushil_Beriwal\/publication\/5492721\/figure\/tbl4\/AS:667083054526470@1536056402522\/Relationship-between-Oncotype-DXt-Recurrence-Score.png\" alt=\"Relationship between Oncotype DXt Recurrence Score | Download Table\" style=\"width: 100%; padding: 5px; background-color: grey;\"><figcaption>Relationship between Oncotype DXt Recurrence Score | Download Table (Tom Baldwin)<\/figcaption><\/figure>\n<p> \t \t<strong>Oncotype Map Testing<\/strong>. <strong>The Oncotype MAP test, previously known as PCDx, provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, allowing physicians to understand a patient&#39;s tumor profile and effectively recommend targeted therapies or clinical trials. Utilities should store and retrieve all pertinent test documentation. Oncotype DX \u00ae tests New Data The only multigene expression genomic test commercially available proven to predict a patient&#39;s individual benefit from chemotherapy. S. and the only one used in breast cancer staging. The Oncotype MAP test, previously known as PCDx, provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, allowing physicians to understand a.<\/strong> Oncotype Map Testing. <\/p>\n<h3>Utilities should store and retrieve all pertinent test documentation.<\/h3>\n<p>Exact also noted that patients who used a previous generation of the test.<\/p>\n<div style=\"display: grid;grid-template-columns: auto auto auto; background: #eee; \">\n<div style=\"padding: 1em;\"> \t\t        <a href=\"https:\/\/image.slidesharecdn.com\/oncotypedx-160307140414\/95\/oncotype-dx-29-638.jpg?cb=1457359476\"><img decoding=\"async\" src=\"https:\/\/image.slidesharecdn.com\/oncotypedx-160307140414\/95\/oncotype-dx-29-638.jpg?cb=1457359476\" onerror=\"this.onerror=null;this.src='https:\/\/tse1.mm.bing.net\/th?id=OIP.27Xle6pfHt-d7XHV8Rq7xAHaFj&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>Oncotype dx<\/p>\n<\/p><\/div>\n<div style=\"padding: 1em;\"> \t\t        <a href=\"https:\/\/www.pharmajournalist.com\/wp-content\/uploads\/2018\/02\/Nucleus-Detect-test-768x576.jpg\"><img decoding=\"async\" src=\"https:\/\/www.pharmajournalist.com\/wp-content\/uploads\/2018\/02\/Nucleus-Detect-test-768x576.jpg\" onerror=\"this.onerror=null;this.src='https:\/\/tse1.mm.bing.net\/th?id=OIP.O75PXI0k2l45tyykdYBzrgHaFj&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>Genomic Health launches Oncotype DX AR-V7 Nuclear Detect Test<\/p>\n<\/p><\/div>\n<div style=\"padding: 1em;\"> \t\t        <a href=\"http:\/\/www.bioworld.com\/sites\/default\/files\/imce\/web_oncotype-dx-graphic.jpg\"><img decoding=\"async\" src=\"http:\/\/www.bioworld.com\/sites\/default\/files\/imce\/web_oncotype-dx-graphic.jpg\" onerror=\"this.onerror=null;this.src='https:\/\/tse4.mm.bing.net\/th?id=OIP.iyQiOVaTz8fkCRbotkXwOwHaDO&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>Oncotype DX could save $50M per year, allow 70% of breast cancer &#8230;<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"display: grid;grid-template-columns: auto auto auto; background: #eee; \">\n<div style=\"padding: 1em;\"> \t\t        <a href=\"https:\/\/www.researchgate.net\/publication\/344127805\/figure\/fig3\/AS:935793996615681@1600122083479\/Oncotype-DX-training-Oncotype-DX-Recurrence-Score-metagenes-and-metagene-weights-A-for_Q640.jpg\"><img decoding=\"async\" src=\"https:\/\/www.researchgate.net\/publication\/344127805\/figure\/fig3\/AS:935793996615681@1600122083479\/Oncotype-DX-training-Oncotype-DX-Recurrence-Score-metagenes-and-metagene-weights-A-for_Q640.jpg\" onerror=\"this.onerror=null;this.src='https:\/\/tse2.mm.bing.net\/th?id=OIP.0zM8qNHi-GgirD-Az6B9VQHaHa&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>Oncotype DX training. Oncotype DX Recurrence Score metagenes and &#8230;<\/p>\n<\/p><\/div>\n<div style=\"padding: 1em;\"> \t\t        <a href=\"https:\/\/rethinkbreastcancer.com\/wp-content\/uploads\/2015\/11\/image003.jpg\"><img decoding=\"async\" src=\"https:\/\/rethinkbreastcancer.com\/wp-content\/uploads\/2015\/11\/image003.jpg\" onerror=\"this.onerror=null;this.src='https:\/\/tse3.mm.bing.net\/th?id=OIP.jK0GfPYHa456EXJxhzQo3AAAAA&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>A Plea to the Government From a Young Woman with Breast Cancer &#8230;<\/p>\n<\/p><\/div>\n<div style=\"padding: 1em;\"> \t\t        <a href=\"https:\/\/i.vimeocdn.com\/video\/1302738160-0b88c4cbcbeb21bf114220109e28bea8d420c1d68953662d4_640x360?r=pad\"><img decoding=\"async\" src=\"https:\/\/i.vimeocdn.com\/video\/1302738160-0b88c4cbcbeb21bf114220109e28bea8d420c1d68953662d4_640x360?r=pad\" onerror=\"this.onerror=null;this.src='https:\/\/tse1.mm.bing.net\/th?id=OIP.yDXZi98Gbo9FC5pExlsIMwHaEK&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>About the Oncotype MAP Pan-Cancer Tissue Test for Urology| Oncotype IQ\u00ae<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"display: grid;grid-template-columns: auto auto auto; background: #eee; \">\n<div style=\"padding: 1em;\"> \t\t        <a href=\"http:\/\/www.oncotypeiq.com\/-\/media\/OIQ\/Colon\/CRS_Sample_Report_page-2.jpg\"><img decoding=\"async\" src=\"http:\/\/www.oncotypeiq.com\/-\/media\/OIQ\/Colon\/CRS_Sample_Report_page-2.jpg\" onerror=\"this.onerror=null;this.src='https:\/\/tse3.mm.bing.net\/th?id=OIP.9vzWYONMlXdMjZ5L-ce7BwHaJY&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>About the Oncotype DX Colon Recurrence Score\u00ae | Oncotype IQ\u00ae<\/p>\n<\/p><\/div>\n<div style=\"padding: 1em;\"> \t\t        <a href=\"https:\/\/image.slidesharecdn.com\/oncotypedx-mammaprint-100219160156-phpapp01\/95\/oncotype-dx-mammaprint-12-728.jpg?cb=1266595371\"><img decoding=\"async\" src=\"https:\/\/image.slidesharecdn.com\/oncotypedx-mammaprint-100219160156-phpapp01\/95\/oncotype-dx-mammaprint-12-728.jpg?cb=1266595371\" onerror=\"this.onerror=null;this.src='https:\/\/tse1.mm.bing.net\/th?id=OIP.Cb0O9YOHpuBwxUYojBdmkgHaFj&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>Oncotype Dx Mammaprint<\/p>\n<\/p><\/div>\n<div style=\"padding: 1em;\"> \t\t        <a href=\"https:\/\/image.slidesharecdn.com\/oncotypedx-mammaprint-100219160156-phpapp01\/95\/oncotype-dx-mammaprint-14-728.jpg?cb=1266595371\"><img decoding=\"async\" src=\"https:\/\/image.slidesharecdn.com\/oncotypedx-mammaprint-100219160156-phpapp01\/95\/oncotype-dx-mammaprint-14-728.jpg?cb=1266595371\" onerror=\"this.onerror=null;this.src='https:\/\/tse1.mm.bing.net\/th?id=OIP.cqzUF1qI3ypNS_DNI6i6xAHaFj&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>Oncotype Dx Mammaprint<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"display: grid;grid-template-columns: auto auto auto; background: #eee; \">\n<div style=\"padding: 1em;\"> \t\t        <a href=\"https:\/\/image.slidesharecdn.com\/oncotypedx-160307140414\/95\/oncotype-dx-48-638.jpg?cb=1457359476\"><img decoding=\"async\" src=\"https:\/\/image.slidesharecdn.com\/oncotypedx-160307140414\/95\/oncotype-dx-48-638.jpg?cb=1457359476\" onerror=\"this.onerror=null;this.src='https:\/\/tse3.mm.bing.net\/th?id=OIP.yaYDiFTMnDkA5g78yEsQzQHaFj&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>Oncotype dx<\/p>\n<\/p><\/div>\n<div style=\"padding: 1em;\"> \t\t        <a href=\"https:\/\/www.multivu.com\/players\/English\/8098751-genomic-health-oncotype-dx-genomic-prostate-score\/image\/oncotypedx-1494442185845-15-HR.jpg\"><img decoding=\"async\" src=\"https:\/\/www.multivu.com\/players\/English\/8098751-genomic-health-oncotype-dx-genomic-prostate-score\/image\/oncotypedx-1494442185845-15-HR.jpg\" onerror=\"this.onerror=null;this.src='https:\/\/tse3.mm.bing.net\/th?id=OIP.kMFUVIgcdZ9vaP3xPfj39wHaEH&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>Oncotype DX\u00ae Genomic Prostate Score\u2122 (GPS) Test Predicts<\/p>\n<\/p><\/div>\n<div style=\"padding: 1em;\"> \t\t        <a href=\"https:\/\/i.ytimg.com\/vi\/aEzzQ2Egxt4\/maxresdefault.jpg\"><img decoding=\"async\" src=\"https:\/\/i.ytimg.com\/vi\/aEzzQ2Egxt4\/maxresdefault.jpg\" onerror=\"this.onerror=null;this.src='https:\/\/tse1.mm.bing.net\/th?id=OIP.JR6jgPJLQwv052coQwLDjQHaEK&amp;pid=Api';\" style=\"width:100%;margin-top: 8px;vertical-align: middle;\"><\/a> \t\t        <\/p>\n<p>The Oncotype DX Test: Understanding Your Breast Cancer Tumor &#8211; YouTube<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<p><strong>Oncotype Map Testing<\/strong>. <strong>Other tumor profiling tests, such as MammaPrint \u00ae, are available. The Oncotype MAP test, previously known as PCDx, is a rapid, comprehensive tumor profiling panel that aids therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer. Oncotype DX \u00ae tests New Data The only multigene expression genomic test commercially available proven to predict a patient&#39;s individual benefit from chemotherapy. For more information, please visit our U. Rick Haney a Soil Chemist and Microbiologist at the ARS Grassland, Soil and Water Research Labor atory The Oncotype MAP test, previously known as PCDx, provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, allowing physicians to understand a patient&#39;s tumor profile and effectively recommend targeted therapies or clinical trials.<\/p>\n<p><\/strong> Oncotype Map Testing.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Oncotype Map Testing. These tests can help medical professionals. The Oncotype MAP test, previously known as PCDx, provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, allowing physicians to understand a. The Oncotype MAP test, previously known as PCDx, is a rapid, comprehensive tumor profiling panel that aids therapy selection for patients [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/w2.geleleger.nl\/wp-json\/wp\/v2\/posts\/985"}],"collection":[{"href":"https:\/\/w2.geleleger.nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/w2.geleleger.nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/w2.geleleger.nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/w2.geleleger.nl\/wp-json\/wp\/v2\/comments?post=985"}],"version-history":[{"count":0,"href":"https:\/\/w2.geleleger.nl\/wp-json\/wp\/v2\/posts\/985\/revisions"}],"wp:attachment":[{"href":"https:\/\/w2.geleleger.nl\/wp-json\/wp\/v2\/media?parent=985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/w2.geleleger.nl\/wp-json\/wp\/v2\/categories?post=985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/w2.geleleger.nl\/wp-json\/wp\/v2\/tags?post=985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}